X

Trial Profile

Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 692342 (Primary)
Indications Tuberculosis
Focus Proof of concept; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

29 Oct 2019 According to a GlaxoSmithKline media release, this study was conducted in partnership with IAVI.
29 Oct 2019 According to a GlaxoSmithKline media release, final analysis of this trial were presented at the 50th Union World Conference on Lung Health.
29 Oct 2019 Final results presented in a GlaxoSmithKline media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com